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Significant advances in the management of cardiovascular disease have been made possible by
the development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase
inhibitors—“statins.” Initial studies explored the impact of statin therapy on coronary artery
disease (CAD) progression and regression. Although the angiographic changes were small,
associated clinical responses appeared significant. Subsequent large prospective placebo-
controlled clinical trials with statins demonstrated benefit in the secondary and primary
prevention of CAD in subjects with elevated cholesterol levels. More recently, the efficacy of
statins has been extended to the primary prevention of CAD in subjects with average
cholesterol levels. Recent studies also suggest that statins have benefits beyond the coronary
vascular bed and are capable of reducing ischemic stroke risk by approximately one-third in
patients with evidence of vascular disease. In addition to lowering low-density lipoprotein
(LDL) cholesterol, statin therapy appears to exhibit pleiotropic effects on many components
of atherosclerosis including plaque thrombogenicity, cellular migration, endothelial function
and thrombotic tendency. Growing clinical and experimental evidence indicates that the
beneficial actions of statins occur rapidly and yield potentially clinically important anti-
ischemic effects as early as one month after commencement of therapy. Future investigations
are warranted to determine threshold LDL values in primary prevention studies, and to
elucidate effects of statins other than LDL lowering. Finally, given the rapid and protean
effects of statins on determinants of platelet reactivity, coagulation, and endothelial function,
further research may establish a role for statin therapy in acute coronary syndromes. (J Am
Coll Cardiol 2000;35:1–10) © 1999 by the American College of Cardiology
Recent advances in the management of hypercholesterol-
emia are primarily due to the development of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG CoA) reductase inhib-
itors or “statins.” The discovery of statins led to important
improvements in the primary and secondary prevention of
coronary artery disease (CAD). Initial studies explored the
impact of statin therapy on CAD progression and regres-
sion. Although angiographic changes in response to therapy
were modest, accompanying clinical benefit appeared sig-
nificant. Subsequent large prospective clinical trials have
provided unequivocal evidence that cholesterol-lowering
therapy with this class of compounds not only reduces the
major coronary event rate in primary and secondary preven-
tion, but also reduces all-cause mortality in secondary
prevention. This review describes the evolving impact of this
class of compounds from their debut in angiographic trials
to their subsequent prominence in large primary and sec-
ondary prevention studies. Additionally, we explore the
pleiotropic actions of statins in reducing atherosclerosis and
its complications.
MECHANISM OF ACTION
AND PHARMACOLOGY OF STATINS
HMG CoA reductase is the rate-limiting enzyme for
cholesterol formation in the liver and other tissues; HMG
CoA reductase responds to negative feedback regulation by
both sterol and nonsterol products of mevalonate metabo-
lism through decreased reductase gene expression (1). By
inhibiting HMG CoA reductase, statins reduce the hepa-
tocyte cholesterol content and increase expression of low-
density lipoprotein (LDL) receptors, responsible for LDL
cholesterol uptake via receptor-mediated endocytosis (Fig.
1). Additionally, a second mechanism of LDL reduction
may relate to LDL and very-low-density lipoprotein
(VLDL) interactions. However, increases in HMG CoA
reductase synthesis shortly after statin therapy restore cel-
lular VLDL levels, and the ultimate effect of reductase
inhibition is enhanced LDL receptor expression and lower
plasma LDL in the setting of normal cellular cholesterol
content.
Statins differ in absorption, plasma protein binding,
excretion and solubility (Table 1) and exhibit variable
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dose-related efficacy in reducing LDL. In addition to
lowering LDL, statins cause relatively small reductions in
triglyceride levels (5% to 10%) in conjunction with minor
increases in high-density lipoprotein (HDL) cholesterol
(5% to 10%), and statin therapy does not reduce lipoprotein
(a) (2). Most common adverse effects associated with statin
therapy are mild, transient, reversible, and include dyspep-
sia, abdominal pain and flatulence. However, the most
important adverse reactions are elevations in serum
transaminases and the development of myositis. The risk of
myositis increases in patients receiving statins in conjunc-
tion with gemfibrozil, nicotinic acid or macrolides, and
there is an appreciable risk of myositis in patients also
receiving cyclosporine (3). Administration of drugs that
inhibit cytochrome P450, such as azole antifungals, cimeti-
dine and methotrexate, also increases the likelihood of
adverse effects.
REGRESSION OF ATHEROSCLEROSIS
Although vascular remodeling occurs naturally in the evo-
lution of atherosclerosis (4), it was hypothesized that the
introduction of cholesterol-lowering therapy would pro-
mote regression and/or retard the progression of atheroma.
Trials with nonstatin compounds such as the Lipid Re-
search Clinics Coronary Primary Prevention Trial using
cholestyramine (5), and the Helsinki Heart Study (6) using
gemfibrozil, supported this hypothesis and demonstrated
significant reductions in coronary events. Thus, a number of
trials (7–14) were conceived to explore the impact of statin
therapy on the progression of coronary atherosclerosis using
both quantitative and nonquantitative coronary angiography
(Table 2). Although these angiographic trials were not
powered to examine clinical outcomes, the relatively small
angiographic changes reported were accompanied by an
unexpected clinical benefit. More recently, the beneficial
effects of statin treatment on vein graft atherosclerosis were
addressed in the Post Coronary Artery Bypass Graft (Post
CABG) Trial (15); aggressive LDL reduction to a mean of
95 mg/dl led to a 31% reduction in the likelihood of
progression of graft atherosclerosis and a 29% reduction in
the rate of revascularization.
Although these angiographic studies used different
patient-selection criteria, different baseline cholesterol levels
and variable doses and duration of therapy, they demon-
strated that plaque progression is common without therapy
(40% to 50% of patients) and is reduced by more than
one-third with statin therapy. Although clear plaque regres-
sion is uncommon (;10% of patients) without therapy, the
frequency of regression more than doubles with statins.
Because these trials were designed to explore the anatomic
impact of statin therapy they were not powered to assess
clinical outcome. Nonetheless, small anatomic changes were
accompanied by a greater reduction in clinical events than
expected based on the angiographic measures, suggesting
that statin therapy may cause regression of lipid-rich lesions
prone to rupture (16) and/or that statin therapy modulates
atherosclerosis through mechanisms independent of ana-
tomic regression (17). These trials provided an important
foundation for subsequent large outcome studies.
STATINS AND CARDIOVASCULAR EVENTS
Landmark clinical trials have demonstrated that HMG
CoA reductase inhibitors not only reduce CAD morbidity
and mortality but also increase survival in the setting of both
hypercholesterolemia or normocholesterolemia (Table 3).
The Scandinavian Simvastatin Survival Study (4S) provided
the first evidence that cholesterol-lowering therapy can
reduce all-cause mortality in subjects with a history of
angina pectoris or myocardial infarction (MI) (18). This
study of 4,444 men and women with total cholesterol levels
of 212 to 310 mg/dl (5.5 to 8.0 mmol/liter) initially used
simvastatin at 20 mg/day and then titrated the drug to 10 or
40 mg/day. At five years, all-cause mortality was reduced by
30%, major coronary event rate by 34% and the coronary
death rate by 42%. The dramatic results of the 4S study
were extended in the West of Scotland Coronary Prevention
Study (WOSCOPS), which was a primary-prevention trial
of pravastatin 40 mg daily in 6,595 men with mean total
cholesterol levels of 272 mg/dl (7.0 mmol/liter) but without
documented CAD (19). After an average of 4.9 years of
follow-up, all-cause mortality was nonsignificantly reduced
by 22% (p 5 0.051), but nonfatal MI or death from CAD
was significantly reduced by 31% and the CAD death rate
reduced by 28%. The need for coronary angiography and
revascularization was also significantly lower in the treated
group. The Cholesterol and Recurrent Events (CARE) trial
was a secondary prevention trial of pravastatin 40 mg daily
Abbreviations and Acronyms
AFCAPS/TexCAPS 5 Air Force/Texas Coronary
Atherosclerosis Prevention
Study
CAD 5 coronary artery disease
CARE 5 Cholesterol and Recurrent
Events trial
HDL 5 high-density lipoprotein
cholesterol
HMG CoA 5 3-hydroxy-3-methylglutaryl
coenzyme A
LDL 5 low-density lipoprotein
cholesterol
LIPID 5 Long-term Intervention with
Pravastatin in Ischemic Disease
study
MI 5 myocardial infarction
NCEP 5 National Cholesterol Education
Program
4S 5 Scandinavian Simvastatin
Survival Study
WOSCOPS 5 West of Scotland Coronary
Prevention Study
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in 4,159 men and women who had an acute MI between 3
and 20 months before randomization and in whom the total
cholesterol level was ,240 mg/dl (6.2 mmol/liter) with an
LDL level of 115 to 174 mg/dl (3.0 to 4.5 mmol/liter) (20).
The primary end point of fatal coronary event or nonfatal
MI was reduced by 24%, and the need for coronary artery
bypass surgery was reduced by 26%. Finally, the CARE
study also demonstrated that women experienced a major
reduction in risk for coronary events and stroke, with benefit
evident beginning at one year (21). It is noteworthy that
statins not only reduce overall cardiovascular mortality but
also reduce sudden death by a similar order of magnitude as
other cardiovascular events (18). The observed reduction in
sudden death may be due to reduced plaque rupture and
reduced acute ischemia.
Recent studies have confirmed and extended these results.
The Air Force/Texas Coronary Atherosclerosis Prevention
Study (AFCAPS/TexCAPS) (22) investigated 6,605 men
and women without clinical evidence of CAD, with an
average LDL level (130 to 190 mg/dl) with below average
HDL cholesterol level (,50 mg/dl), and who were treated
with placebo or lovastatin titrated up to 40 mg daily to
achieve an LDL level less than 110 mg/dl. After 4.8 years of
follow-up, the incidence of first major acute coronary event
Figure 1. Regulation of cholesterol synthesis. Inhibition of HMG CoA reductase reduces intracellular cholesterol levels, thus activating
a protease, which in turn cleaves sterol regulatory element-binding proteins (SREBPs) from the endoplasmic reticulum. The SREBPs
translocate to the nucleus where they upregulate expression of the LDL receptor gene. Enhanced LDL receptor expression increases
receptor-mediated endocytosis of LDL and thus lowers serum LDL. Inhibition of HMG CoA reductase also reduces intracellular levels
of isoprenoids, which are intermediates in cholesterol biosynthesis.
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was reduced by 37% in the treated group. The Long-term
Intervention with Pravastatin in Ischemic Disease study
(LIPID) (23) was a secondary prevention study to compare
pravastatin 40 mg daily to placebo in 9,014 men and women
with prior MI or unstable angina and total cholesterol levels
between 155 and 271 mg/dl. After a mean follow-up of 6.1
years, all-cause mortality was reduced by 22%, mortality due
to CAD by 24%, and stroke by 19%.
These trials have unequivocally shown that lowering
LDL increases survival by both secondary and primary
prevention of CAD not only in individuals with elevated
LDL levels, but also in those with average LDL levels. The
evidence to date suggests that statin therapy should reduce
the clinical consequences of atherosclerosis in a large pro-
portion of the population at risk. These studies have raised
questions regarding the relative appropriate pretreatment
LDL levels in both primary and secondary CAD prevention
and the degree to which LDL should be lowered. The
relative reduction in LDL achieved in these trials is depicted
in Figure 2.
The results of 4S, CARE and LIPID indicate that statin
therapy is highly beneficial in CAD secondary prevention
for patients with both elevated and average LDL levels.
Thus, most patients with CAD will benefit from statin
therapy. Although CARE suggested that no further risk
reduction occurs by lowering LDL below 125 mg/dl, this
lower threshold remains controversial. The Post CABG
trial demonstrated reduced saphenous vein graft atheroscle-
rosis and reduced need for revascularization in patients in
whom LDL was aggressively lowered to a mean of 95 mg/dl
(15). The National Cholesterol Education Program
(NCEP) has established guidelines for cholesterol manage-
ment (24) in patients with CAD or peripheral atheroscle-
rotic disease; the recommended goal is an LDL of #100
mg/dl. Recently published subgroup analyses from 4S and
CARE indicate that these NCEP guidelines for secondary
prevention of CAD are generally appropriate (25,26). It will
be important to determine whether further aggressive LDL
lowering will yield additional benefit, especially in sub-
groups of patients with advanced atherosclerosis.
The WOSCOPS trial (19,27) provides strong evidence
that cholesterol-lowering therapy is effective in primary
prevention in patients with high LDL. However,
WOSCOPS did not give a clear indication of the optimal
Table 1. Pharmacologic Characteristics of Different HMG CoA Reductase Inhibitors
Drug
Daily
Dose (mg)
Absorption
(%)
Plasma Protein
Binding (%)
Renal
Excretion
(%)
Half-life
(h) Solubility
Lovastatin 20–80 31 95 30 2–3 Lipophilic
Simvastatin 5–80 60–85 98 13 2–3 Lipophilic
Pravastatin 10–40 35 40–50 60 1–3 Hydrophilic
Fluvastatin 20–80 98 99 6 0.5–1 Hydrophilic
Atorvastatin 10–80 NA 98 2 13–16 Lipophilic
Cerivastatin 0.2–0.3 NA 99 24 2–3 NA
NA 5 not available.
Table 2. Summary of Major Angiographic Trials of the Effects of Statins on Coronary Artery Disease
Study
(Reference) Study Description
Duration
(yrs)
% Red
LDL-C Control Treatment
Clinical
Events
FATS (7) 146 pts 2.5 46 46% Prog 21% Prog Decreased
Lovastatin 40–80 mg/d (1colestipol) 11% Regr 32% Regr
MARS (8) 270 pts 2.2 38 41% Prog 29% Prog NS reduction
Lovastatin 40 mg bid 12% Regr 23% Regr
CCAIT (9) 331 pts 2 29 50% Prog 33% Prog NS reduction
Lovastatin 20–80 mg/d 7% Regr 10% Regr
MASS (10) 381 pts 4 31.4 32% Prog 23% Prog NS reduction
Simvastatin 20 mg/d 12% Regr 18% Regr
REGRESS (11) 885 pts 2 29 NA NA Decreased
Pravastatin 40 mg/d
PLAC-I (12) 408 pts 3 28 50% Prog 37% Prog Decreased
Pravastatin 40 mg/d 15% Regr 21% Regr
CIS (13) 254 pts 2.3 35 53.5 Prog 34.6 Prog No difference
Simvastatin 40 mg/d 12.9% Regr 18.3 Regr
LCAS (14) 340 pts 2.5 23.9 39.1% Prog 28.7% Prog
Fluvastatin 20 mg bid 8.3% Regr 14.6% Regr NS reduction
Prog 5 progression; Regr 5 regression; NS 5 nonsignificant; NA 5 not available.
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LDL cholesterol for the initiation of statin therapy in this
setting. The AFCAPS/TexCAPS study revealed that men
and women with average LDL and without evidence of
vascular disease also derived benefit from statin therapy.
Although the NCEP recommends for primary prevention a
minimal goal of LDL ,160 mg/dl, and in patients with a
high burden of risk factors a goal ,130 mg/dl, AFCAPS/
TexCAPS data support benefit of statin therapy at LDL
levels below those currently targeted by the NCEP guide-
lines. Based on these findings, it would now seem, at
minimum, prudent to apply aggressively the NCEP guide-
lines in the primary prevention of vascular disease. How-
ever, given the absence of reduction in overall mortality with
statin therapy in AFCAPS/TexCAPS, further studies are
warranted to explore the benefit of achieving target choles-
terol levels as outlined by the NCEP. It is possible that in
high-risk patients it may be appropriate to lower LDL even
further. Aggressive LDL lowering may be achieved through
combination therapy of statins with other lipid-lowering
drugs. Additional studies are warranted to address these
important questions.
STATINS AND CEREBROVASCULAR DISEASE
Despite the established role of cholesterol in the pathogen-
esis of CAD, current evidence does not demonstrate a clear
relationship between the risk of stroke and plasma choles-
terol level (28,29). Despite a paucity of clear epidemiologic
evidence of a relationship between plasma cholesterol and
stroke risk, recent studies indicate that statins have benefi-
cial effects that extend beyond the coronary vascular bed
(30,31). Clinical benefit of statins is also supported by
imaging studies showing reversal of carotid intimal-medial
thickening by statins (32–34). In the CARE study, prava-
statin significantly reduced the specified end point stroke by
31%, without increased hemorrhagic stroke (20). Post hoc
Figure 2. LDL lowering in primary and secondary prevention trials of statin therapy. The mean LDL enrollment levels are depicted for
major trials testing statin utility in primary prevention (WOSCOPS, AFCAPS) and secondary prevention (4S, CARE, LIPID) of
coronary artery disease. Mean LDL levels achieved after statin therapy in each trial are also depicted. The NCEP-recommended goals for
LDL lowering are depicted for both primary and secondary CAD prevention. Note that mean LDL levels achieved with statins in the
AFCAPS primary prevention trial to determine drug efficacy are lower than the NCEP goals. (*Absolute value extrapolated from a
reported 25% reduction in LDL [23]).
Table 3. Summary of Major Clinical Intervention Trials of the Effects of Statins on Coronary Events and Stroke
Trial (Reference) Study Description
Duration
(yrs)
Reduction
LDL-C
(%)
Mortality
(%)
CAD Death
(%)
Stroke
(%)
4S (18) 4,444 pts, HC, CAD, 5.0 35 30 42 30
Simvastatin 10–40 mg/d
WOSCOPS (19) 6,595 pts, HC, No CAD 4.9 26 22 (NS) 33 11 (NS)
Pravastatin 40 mg/d
CARE (20) 4,159 pts, NC, CAD 5.0 28 8 (NS) 19 31
Pravastatin 40 mg/d
AFCAPS/TexCAPS (22) 6,605 pts, NC, No CAD 5.2 25 NA 36 NA
Lovastatin 20–40 mg/d
LIPID (23) 9,014 pts, NC, CAD 6.1 25 22 24 19
Pravastatin 40 mg/d
HC 5 hypercholesterolemia; NC 5 normocholesterolemia; CAD 5 coronary artery disease; NS 5 not significant; NA 5 not available.
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analysis of the 4S trial (18) showed a similarly significant
reduction in stroke. In the WOSCOPS primary prevention
trial, a nonsignificant 11% reduction in stroke was noted
during five-year follow-up (19). Furthermore, two meta-
analyses indicate that statin therapy lowers stroke risk by
about 30%, an extent comparable to aspirin (31,35).
ANTI-ISCHEMIC PROPERTIES OF STATINS
In addition to angiographic and clinical outcome studies,
several investigators have explored the impact of statin
therapy on the endothelial control of vasomotor tone in
hypercholesterolemic patients (36–38). Improvement in
coronary vasomotor function may be seen after as little as six
months of therapy (36). Decreased vasospasm is also sug-
gested by improved forearm blood flow in hypercholester-
olemic patients treated with statins for only four weeks (39).
The relationship between LDL reduction and amelioration
of endothelial dysfunction in hypercholesterolemia is sup-
ported by the observation that single-session LDL apheresis
improves forearm blood flow (40). Improvement in myo-
cardial perfusion, reported to occur after only three months
of statin therapy, may relate to decreased vasospasm (41,42).
Electron-beam–computed tomography has recently shown
that statins reduce the volume of calcified plaque in coronary
arteries in 12 months (43). This radiographic surrogate
suggests that statins may alter the constituents and behavior
of plaque, rendering it more stable. Ultimately, the anti-
ischemic effect of statin therapy can also be directly shown
with quantitative ST-segment monitoring during 24-h am-
bulatory electrocardiography (44,45).
PLAQUE STABILIZATION
Atherogenesis is initiated by accumulation of LDL in the
subendothelial space, where it becomes oxidized to mini-
mally modified LDL (46), which induces local production
of monocyte chemotactic protein 1 (MCP1) as well as other
chemotactic factors that recruit additional leukocytes to the
arterial wall (47). Oxidized LDL attracts macrophages
directly (48) and stimulates their binding to the endothe-
lium through induction of adhesion molecules such as
P-selectin (49) and vascular cell adhesion molecule 1
(VCAM-1) (50). The HMG-CoA reductase inhibitors
prevent the oxidation of LDL (51) possibly through pres-
ervation of the activity of the endogenous antioxidant
system, superoxide dismutase (52). Statins also alter mac-
rophage handling and uptake of LDL. Lovastatin not only
inhibits oxidation of LDL, but also reduces the avidity with
which macrophages ingest oxidized LDL (51). Reduced
LDL oxidation and uptake by macrophages may be due to
direct effects of statins on LDL, which change its propensity
for oxidization (51). Statins also reduce vascular expression
of adhesion molecules (53,54). In humans, both simvastatin
and lovastatin reduce monocyte CD11b expression and ex
vivo CD11b-dependent monocyte adhesion to endothelium
in patients with hypercholesterolemia (55).
The monocyte/macrophage is not only a promiscuous
initiator of atherosclerosis but also a central orchestrator of
plaque rupture, the event which heralds most acute coronary
syndromes (56). Modified LDL induces macrophage trans-
formation into foam cells and also promotes macrophage
activation, which leads to plaque instability (57). Macro-
phages have been implicated in the pathophysiology of acute
coronary syndromes by producing enzymes, including mem-
bers of the metalloproteinase family (interstitial collagenase,
gelatinase, and stromelysin) that digest and weaken the
plaque cap, making disruption more likely (58,59). In
addition, macrophages elaborate tissue factor, a membrane-
bound glycoprotein that plays an integral role in blood
coagulation, and is an important determinant of plaque
thrombogenicity (60). Statin therapy inhibits tissue factor
expression by cultured human macrophages, and this may
reduce thrombotic events (61). In addition to effects on
LDL, macrophage activation, and adhesion molecule ex-
pression, statins may also attenuate atherogenesis through
the inhibition of vascular smooth muscle cell proliferation
and migration (62,63) and thus attenuate plaque growth and
new lesion formation. Interestingly, pravastatin, a hydro-
philic statin, may not share this antiproliferative effect (64),
and yet it shows clinical benefit in angiographic and event
trials. Experimental/clinical disparities such as this raise
questions about the clinical applicability of isolated in vitro
studies of statins.
STATINS AND ENDOTHELIAL DYSFUNCTION
Several lines of evidence indicate that statins biochemically
“modify” the paracrine functions of endothelium in hyper-
cholesterolemia, and transform the endothelium from pre-
dominantly prothrombotic and vasospastic to thromboresis-
tant and vasodilatory. The mechanisms underlying the
benefit of statin therapy on endothelial dysfunction induced
by hypercholesterolemia remain unclear, but hypotheses
center on nitric oxide (NO)-dependent mechanisms. Direct
upregulation of endothelial nitric oxide synthase (eNOS) by
HMG CoA reductase inhibitors has recently been reported,
and this may represent an important mechanism by which
these compounds preserve endothelial NO synthesis (65).
Nitric oxide regulates the paracrine antiatherosclerotic func-
tions of the endothelium, which include inhibition of
leukocyte and platelet adhesion, control of vascular tone and
growth and maintenance of a thromboresistant interface
between the bloodstream and the vessel wall. There is a
growing body of evidence suggesting that impaired NO
synthesis or activity accompanies hypercholesterolemia (66).
Increased concentrations of oxidized LDL may directly
inhibit NO by excess production of oxygen-derived free
radicals and reduced transcription or increased posttransla-
tional destabilization of eNOS mRNA (66). Hypercholes-
terolemia also reduces eNOS activity through cytokine
production (67), or increases in dimethyl arginine, an
endogenous inhibitor of eNOS (68).
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INHIBITION OF ISOPRENOID BIOSYNTHESIS
In addition to lowering intracellular levels of sterols, HMG
CoA reductase inhibitors reduce levels of isoprenoids,
which are derived from intermediates of the cholesterol
biosynthetic pathway (Fig. 1). Isoprenoids posttranslation-
ally prenylate a variety of cellular proteins that play central
roles in both cell growth and in signal transduction path-
ways such as low-molecular weight guanine nucleotide
binding proteins (G-proteins), which have been shown to
modulate signal transduction and mitogenic pathways (69).
Finally, the putative antioxidant effects attributed to statins
(52) may be due to attenuated isoprenylation of NADPH
oxidase, which in its isoprenylated state generates superox-
ide anion (70).
ANTI-THROMBOTIC ACTIONS OF STATINS
Platelets play a fundamental role in atherogenesis and in the
pathophysiology of acute coronary syndromes (71,72). Hy-
percholesterolemia is associated with both hypercoagulabil-
ity as well as enhanced platelet activation (73). High LDL
levels increase platelet reactivity in association with en-
hanced thromboxane A2 (TXA2) biosynthesis, and en-
hanced TXA2 production has been demonstrated in the
majority of patients with type IIa hypercholesterolemia (74).
Hypercholesterolemia has also been associated with in-
creased platelet alpha2 adrenergic receptor density (75),
changes in the composition of platelet membrane phospho-
lipids and cholesterol (76) and increases in platelet cytosolic
calcium (77).
Several studies demonstrate reductions in platelet reac-
tivity with statin treatment (74,78,79). Although the precise
mechanism responsible for the effects of statins on platelet
function is unclear, one mechanism may involve decreased
platelet TXA2 production. The finding that the membrane
cholesterol content of both erythrocytes and platelets is
reduced in patients treated with pravastatin (80) suggests
that certain properties of these membranes are altered in a
manner that renders them less prone to participation in
thrombosis. Moreover, Nofer and colleagues (81) have
recently elucidated a novel mechanism that increases platelet
activation in hypercholesterolemia through inhibition of
platelet Na1/H1 antiport by LDL. Statin therapy also
ameliorates the enhanced thrombotic and reduced fibrino-
lytic state that accompanies hypercholesterolemia (82). Al-
though statins do not directly reduce lipoprotein (a) [Lp(a)]
levels and may even increase levels of this lipoprotein (2),
statins may still modify prothrombotic states related to
simultaneously elevated LDL and Lp(a) (83–85). Addition-
ally, platelet-dependent thrombin generation is increased in
subjects with hypercholesterolemia, and treatment with
pravastatin normalizes thrombin production (86).
These observations add to the growing body of evidence
linking hypercholesterolemia and thrombosis and suggest
that statins reverse the thrombotic-fibrinolytic imbalance
that accompanies hypercholesterolemia. Given that throm-
botic disruption of plaque precipitates most acute coronary
syndromes, the impact of statin therapy in reducing both the
thrombotic tendency of blood, in addition to the thrombo-
genicity of plaque, may be particularly important in the
overall reduction of clinical events.
SUMMARY
Recent advances in the management of hypercholesterol-
emia are largely due to the development of HMG CoA
reductase inhibitors. Initial studies explored the impact of
statin therapy on CAD progression and regression, and
although the angiographic changes were unimpressive, the
accompanying clinical benefit appeared significant. Subse-
quent large prospective clinical trials gave clear evidence that
statin therapy not only reduces major coronary event rate
but also reduces all-cause mortality. For lipid lowering, the
NCEP-defined goals provide targets for statin therapy. For
patients with CAD or other atherosclerotic disease, the
NCEP goal is an LDL of #100 mg/dl. The NCEP
recommends a minimal goal of LDL ,160 mg/dl in
primary prevention, and in patients with a high burden of
risk factors, the recommended goal is LDL ,130 mg/dl.
The anatomic/clinical disparity manifest in clinical trials
may best be explained by effects of statins over and above
lipid lowering: promotion of plaque stability, improvement
of endothelial dysfunction and reversal of coagulation and
platelet abnormalities that accompany hypercholesterol-
emia. Recent studies also suggest that statins have beneficial
effects extending beyond the coronary vascular bed and are
capable of reducing ischemic stroke risk by approximately
one-third in patients with evidence of vascular disease.
Burgeoning clinical and experimental evidence indicates
that the beneficial action of statins occurs rapidly and may
yield clinically important anti-ischemic effects as early as
one month after commencement of therapy. Statins exhibit
pleiotropic effects on many components of atherosclerosis,
including plaque thrombogenicity, cellular migration, endo-
thelial function and thrombotic tendency (Fig. 3). Clinical
benefits of these effects in vivo remains to be determined.
FUTURE DIRECTIONS
Although statin therapy is established as an integral com-
ponent in the management of CAD, many questions
concerning such therapy remain unanswered. The issue of
how far LDL should be lowered is still controversial. The
management of patients with CAD and baseline LDL of
100 to 129 mg/dl needs to be addressed in a specific clinical
trial as well as a study exploring threshold LDL values in
primary prevention. The role of hypertriglyceridemia and its
treatment in patients already receiving statin therapy also
needs prospective evaluation. Several promising small stud-
ies (87,88) should prompt large-scale clinical trials and
meta-analyses of current databases to test utility of other
lipid-lowering drugs in combination with statins in patients
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with a spectrum of dyslipidemias. Further data are also
awaited to support the growing importance of cholesterol as
a risk factor for ischemic stroke and the benefit of statin
therapy in patients with cerebrovascular disease. Elucidation
of statin effects other than LDL lowering will undoubtedly
provide an increasing number of therapeutic goals for statin
therapy. In addition, the role of immediate statin therapy in
patients presenting with acute coronary syndromes is un-
known. Given the rapid and protean effects of statins on
determinants of platelet reactivity, coagulation and endo-
thelial function, future investigation may address a role for
statin therapy in acute coronary syndromes.
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